Known targets — ChEMBL curated mechanism
GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ
The experimentally established mechanism targets of Temazepam. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 known ✓ | P14867 | 8/20 | 0.78 |
| ▸ | GABRG2 known ✓ | P18507 | 8/20 | 0.78 |
| ▸ | GABRB3 known ✓ | P28472 | 8/20 | 0.78 |
| ▸ | GABRA5 known ✓ | P31644 | 8/20 | 0.78 |
| ▸ | GABRA3 known ✓ | P34903 | 8/20 | 0.78 |
| ▸ | GABRA2 known ✓ | P47869 | 8/20 | 0.78 |
| ▸ | GABRB2 known ✓ | P47870 | 5/20 | 0.78 |
| ▸ | GABRP known ✓ | O00591 | 2/20 | 0.78 |
| ▸ | GABRD known ✓ | O14764 | 2/20 | 0.78 |
| ▸ | GABRB1 known ✓ | P18505 | 2/20 | 0.78 |
| ▸ | GABRA4 known ✓ | P48169 | 2/20 | 0.78 |
| ▸ | GABRE known ✓ | P78334 | 2/20 | 0.78 |
| ▸ | GABRA6 known ✓ | Q16445 | 2/20 | 0.78 |
| ▸ | GABRG1 known ✓ | Q8N1C3 | 2/20 | 0.78 |
| ▸ | GABRG3 known ✓ | Q99928 | 2/20 | 0.78 |
| ▸ | GABRQ known ✓ | Q9UN88 | 2/20 | 0.78 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.82 |
| ▸ | LMNA | P02545 | 3/20 | 0.82 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.82 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Temazepam SCHEMBL81963 | 0.90 | OPRK1 (1.00) | OPRK1LMNAPDE3AGABRA1GABRG2 | |
| Temazepam SCHEMBL29463 | 0.90 | OPRK1 (1.00) | OPRK1LMNAPDE3AGABRA1GABRG2 | |
| Temazepam SCHEMBL29464 | 0.90 | OPRK1 (1.00) | OPRK1LMNAPDE3AGABRA1GABRG2 | |
| Temazepam SCHEMBL5503177 | 0.90 | OPRK1 (1.00) | OPRK1LMNAPDE3AGABRA1GABRG2 | |
| Temazepam SCHEMBL29398512 | 0.90 | OPRK1 (1.00) | OPRK1LMNAPDE3AGABRA1GABRG2 | |
| Temazepam SCHEMBL16922195 | 0.90 | OPRK1 (1.00) | OPRK1LMNAPDE3AGABRA1GABRG2 | |
| Temazepam SCHEMBL10480110 | 0.89 | OPRK1 (0.98) | OPRK1LMNAPDE3AGABRA1GABRG2 | |
| Diazepam SCHEMBL10948878 | 0.89 | GABRA1 (0.69) | OPRK1LMNAPDE3AGABRA1GABRG2 | |
| Diazepam SCHEMBL28100552 | 0.88 | GABRA1 (0.95) | OPRK1LMNAPDE3AGABRA1GABRG2 | |
| Diazepam SCHEMBL21442 | 0.88 | GABRA1 (1.00) | OPRK1LMNAPDE3AGABRA1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6586478-B2 | Administering nitrogen oxide mimetic | CELLEGY CANADA (CA) | 2003-07-01 | — | — | US | claimed |
| US-5137730-A | Premixing of citric acid with active drug ingredient by wet granulation; enhanced disintegration and dissolution times | E. R. SQUIBB & SONS, INC. (US) | 1992-08-11 | — | — | US | claimed |
| EP-1351760-A2 | CONTINUOUS PRODUCTION OF PHARMACEUTICAL GRANULATES | WARNER-LAMBERT COMPANY (US) | 2003-10-15 | — | — | EP | disclosed |
| US-20030090039-A1 | Continuous production of pharmaceutical granulation | GHEBRE-SELLASSIE ISAAC (US) | 2003-05-15 | — | — | US | disclosed |
| US-6499984-B1 | Continuous production of pharmaceutical granulation | WARNER-LAMBERT COMPANY | 2002-12-31 | — | — | US | disclosed |
| WO-2001089679-A2 | CONTINUOUS PRODUCTION OF PHARMACEUTICAL GRANULATES | WARNER-LAMBERT COMPANY (US) | 2001-11-29 | — | — | WO | disclosed |